FORT LAUDERDALE, Fla., Aug. 14, 2009 (GLOBE NEWSWIRE) — MAKO Surgical Corp. (Nasdaq:MAKO – News), a medical device company that markets both its RIO(r) Robotic Arm Interactive Orthopedic surgical platform and proprietary RESTORIS(r) implants for minimally invasive orthopedic knee procedures known as MAKOplasty(r), today announced that it has priced its public offering of 7,000,000 shares of its common stock at a price to the public of $7.25 per share. The closing of the offering is expected to take place on August 19, 2009. Piper Jaffray & Co. acted as the sole book-running manager for the offering and Leerink Swann LLC acted as co-manager.
Assuming no exercise of the underwriters’ over-allotment option, MAKO expects to receive gross proceeds from the offering of approximately $50.8 million. MAKO will use the net proceeds of approximately $47.2 million after deducting underwriting discounts and commissions and estimated expenses of the offering to support commercialization, sales, marketing and general administrative activities, for research and product development activities and to fund working capital and other general corporate purposes.
The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained by contacting Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924. Electronic copies of the prospectus and the prospectus supplement are available on the Securities and Exchange Commission’s website at www.sec.gov.
